Chunxia Su

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Low Density Lipoprotein

Locally Advanced

Mesenchymal Stem Cells

Chemotherapy Induced

Top Venues

Cancer medicine

Cancer immunology, immunotherapy : CII

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Li Wang, Yueran Wu, Zhixuan Ren, Xiangling Chu, Jianing Chen, Li Liu, Jing Zhao, Xin Yu, Mengqing Xie, Chunxia Su
A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations. Cancer medicine 13 (12) (2024)
Li Wang, Yueran Wu, Zhixuan Ren, Xiangling Chu, Jianing Chen, Li Liu, Jing Zhao, Xin Yu, Mengqing Xie, Chunxia Su
A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations. Cancer medicine 13 (12) (2024)
Li Wang, Yueran Wu, Zhixuan Ren, Xiangling Chu, Jianing Chen, Li Liu, Jing Zhao, Xin Yu, Mengqing Xie, Chunxia Su
A retrospective study of first-line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations. Cancer medicine 13 (12) (2024)
Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han, Tianqing Chu, Chunxia Su
Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study. Cancer immunology, immunotherapy : CII (2021)
Mengqing Xie, Xin Yu, Xiangling Chu, Huikang Xie, Juan Zhou, Jing Zhao, Chunxia Su
Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer 13 (3) (2021)